CL2009000478A1 - Composicion farmaceutica que comprende piracetam o una sal del mismo, l-carnitina y un vehiculo; proceso de preparacion de la composicion; y su uso para el tratamiento y/o prevencion de trastornos mitocondriales relacionados con efectos colaterales inducidos por farmacos, tal como enfermedad de alzheimer o mal de parkinson. - Google Patents

Composicion farmaceutica que comprende piracetam o una sal del mismo, l-carnitina y un vehiculo; proceso de preparacion de la composicion; y su uso para el tratamiento y/o prevencion de trastornos mitocondriales relacionados con efectos colaterales inducidos por farmacos, tal como enfermedad de alzheimer o mal de parkinson.

Info

Publication number
CL2009000478A1
CL2009000478A1 CL2009000478A CL2009000478A CL2009000478A1 CL 2009000478 A1 CL2009000478 A1 CL 2009000478A1 CL 2009000478 A CL2009000478 A CL 2009000478A CL 2009000478 A CL2009000478 A CL 2009000478A CL 2009000478 A1 CL2009000478 A1 CL 2009000478A1
Authority
CL
Chile
Prior art keywords
disease
pharmaceutical composition
piracetam
carnitine
prevention
Prior art date
Application number
CL2009000478A
Other languages
English (en)
Inventor
Costa Pereira Jose Roberto Falci Marcio Alario Mauricio Matteis Da
Original Assignee
Biolab Sanus Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmaceutica Ltda filed Critical Biolab Sanus Farmaceutica Ltda
Publication of CL2009000478A1 publication Critical patent/CL2009000478A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE; A) PIRACETAM O SUS SALES TARMACEUTICAMENTE ACEPTABLES: (H) L-CARNITINA Y (C) UN VEHICULO FORRNACEUTICAMENTE ACEPTABLE PROCESO DE PREPARACIÓN DE LA PRESENTE LA COMPOSICIÓN DE LA INVENCÓN PUEDE CONTENER, EN FORMA ADICIONAL, UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE POR LO MENOS UN AGENTE TERAPEUTICO ASOCIADO CON TRASTORNO MITOCONDRIAL Y/O METABÓLICO SELECCIONADO DE GRUPO QUE CONSISTE DE S9ENTES HIPOCOLESTEROLÉMICOS, OXIDANTES DE NUCLEÁTIDOS PIRIDINICOS. HORMONAS TIROIDEAS, AGENTES ANTIEPILÉPTICOS Y AGENTES HIPOGLUCÉMICOS. LA INVENCIÓN CAMBIEN INCLUYE EL USO DE LA COMPOSICIÓN FARMACÉUTICA DE LA INVENCIÓN EN (A PREPARACIÓN DE UN MEDICAMENLO PARA EL TRATAMIENTO YO PREVENCIÓN DE TRASTORNOS MITOCONDRIALES RELACIONADOS CON EFECTOS COLATERALES INDUCIDOS POR FARMACOS USADOS ART UN MAMIFERO, TAL COMO ENFERMEDAD DE ALZHELMER Y MAL DE PART(NSON.
CL2009000478A 2008-02-29 2009-02-27 Composicion farmaceutica que comprende piracetam o una sal del mismo, l-carnitina y un vehiculo; proceso de preparacion de la composicion; y su uso para el tratamiento y/o prevencion de trastornos mitocondriales relacionados con efectos colaterales inducidos por farmacos, tal como enfermedad de alzheimer o mal de parkinson. CL2009000478A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0800432 2008-02-29

Publications (1)

Publication Number Publication Date
CL2009000478A1 true CL2009000478A1 (es) 2009-08-07

Family

ID=41016503

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000478A CL2009000478A1 (es) 2008-02-29 2009-02-27 Composicion farmaceutica que comprende piracetam o una sal del mismo, l-carnitina y un vehiculo; proceso de preparacion de la composicion; y su uso para el tratamiento y/o prevencion de trastornos mitocondriales relacionados con efectos colaterales inducidos por farmacos, tal como enfermedad de alzheimer o mal de parkinson.

Country Status (20)

Country Link
US (1) US20110052556A1 (es)
EP (1) EP2262495B1 (es)
JP (1) JP5677856B2 (es)
KR (1) KR101686917B1 (es)
CN (1) CN102014896A (es)
AR (1) AR070713A1 (es)
AU (1) AU2009219050B2 (es)
CA (1) CA2716020C (es)
CL (1) CL2009000478A1 (es)
CO (1) CO6400019A1 (es)
ES (1) ES2699458T3 (es)
HU (1) HUE042168T2 (es)
IL (1) IL207852A (es)
MX (1) MX2010009290A (es)
PE (1) PE20091564A1 (es)
PL (1) PL2262495T3 (es)
PT (1) PT2262495T (es)
TR (1) TR201820411T4 (es)
WO (1) WO2009105853A2 (es)
ZA (1) ZA201006031B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525899B (zh) * 2012-01-17 2013-04-17 山东罗欣药业股份有限公司 一种奥拉西坦组合物注射液及其制备方法
CN103099211A (zh) * 2012-12-21 2013-05-15 洪万雄 一种融合辅酶q10的广谱性一氧化氮保健品
LV15003B (lv) * 2013-10-22 2015-08-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
CN108853029A (zh) * 2018-09-07 2018-11-23 南通雅本化学有限公司 一种罗苏伐他汀的制备方法
WO2022231257A1 (ko) * 2021-04-26 2022-11-03 주식회사 케이에스비튜젠 옥시라세탐을 포함하는 근육질환 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
CA2007983C (en) * 1989-01-18 1996-12-10 Michael S. Brown Coenzyme q10 with hmg-coa reductase inhibitors
US5316765A (en) 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
AU782188B2 (en) * 1999-06-08 2005-07-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antilipemic combinations comprising HMG-COA reductase inhibitors and carnitines
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
KR100846641B1 (ko) 2000-05-09 2008-07-16 카네카 코포레이션 동맥경화 억제 방법 및 조성물
US20020058026A1 (en) * 2000-11-13 2002-05-16 Milton Hammerly HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1613590A2 (en) * 2003-04-16 2006-01-11 Memory Pharmaceutical Corporation 4-(3,4-disubstituted phenyl)-pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CA2604629A1 (en) * 2005-04-11 2006-10-19 The Trustees Of Columbia University In The City Of New York Methods for treating mild cognitive impairment
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress

Also Published As

Publication number Publication date
JP2011513246A (ja) 2011-04-28
PE20091564A1 (es) 2009-11-04
KR20100126454A (ko) 2010-12-01
EP2262495A4 (en) 2012-01-11
EP2262495B1 (en) 2018-10-31
JP5677856B2 (ja) 2015-02-25
CA2716020A1 (en) 2009-09-03
AU2009219050A1 (en) 2009-09-03
WO2009105853A3 (en) 2009-11-26
AU2009219050B2 (en) 2014-04-24
CO6400019A1 (es) 2012-03-15
PL2262495T3 (pl) 2019-03-29
MX2010009290A (es) 2010-09-14
KR101686917B1 (ko) 2016-12-15
IL207852A (en) 2015-07-30
CN102014896A (zh) 2011-04-13
HUE042168T2 (hu) 2019-06-28
ES2699458T3 (es) 2019-02-11
PT2262495T (pt) 2019-02-04
AR070713A1 (es) 2010-04-28
WO2009105853A8 (en) 2010-02-18
ZA201006031B (en) 2012-01-25
WO2009105853A2 (en) 2009-09-03
EP2262495A2 (en) 2010-12-22
TR201820411T4 (tr) 2019-01-21
US20110052556A1 (en) 2011-03-03
IL207852A0 (en) 2010-12-30
CA2716020C (en) 2018-10-16

Similar Documents

Publication Publication Date Title
CY1122417T1 (el) Μεθοδοι και συνθεσεις για παρατεταμενη παροχη φαρμακων
DOP2017000105A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
PE20171095A1 (es) Acidos grasos novedosos y su uso en la conjugacion con biomoleculas
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2015004644A (es) Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados.
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
CL2009000478A1 (es) Composicion farmaceutica que comprende piracetam o una sal del mismo, l-carnitina y un vehiculo; proceso de preparacion de la composicion; y su uso para el tratamiento y/o prevencion de trastornos mitocondriales relacionados con efectos colaterales inducidos por farmacos, tal como enfermedad de alzheimer o mal de parkinson.
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
IN2015DN03219A (es)
CR11418A (es) Trans-clomifeno para el sindrome metabolico
CL2012002175A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprende un agente activo de fracciones de propargilamina y aminoindano; metodo de preparacion; uso en el tratamiento de enfermedades neurodegenerativas o lesiones en el sistema nervioso tales como parkinson o alzheimer, un accidente cerebrovascular o lesion traumatica cerebral.
MX367131B (es) Sales de xantilio 3,6-disustituidas.
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
BR112015030431A2 (pt) formulação de liberação modificada
MA32635B1 (fr) Produit medicamenteux et traitement associe
JP2018524306A5 (es)
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
GT200800235A (es) Formulacion de medicamento liquida
WO2010066437A3 (de) Wässrige zusammensetzung enthaltend dexpanthenol und natriumchlorid
CL2022000611A1 (es) Hidrogel superporoso plastificado